[go: up one dir, main page]

BRPI0413277A - composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas - Google Patents

composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas

Info

Publication number
BRPI0413277A
BRPI0413277A BRPI0413277-7A BRPI0413277A BRPI0413277A BR PI0413277 A BRPI0413277 A BR PI0413277A BR PI0413277 A BRPI0413277 A BR PI0413277A BR PI0413277 A BRPI0413277 A BR PI0413277A
Authority
BR
Brazil
Prior art keywords
lipophilic microphase
pharmaceutical compositions
forming materials
amorphous drug
microphase forming
Prior art date
Application number
BRPI0413277-7A
Other languages
English (en)
Inventor
Walter Christian Babcock
Dwayne Thomas Friesen
Ravi Mysore Shanker
Daniel Tod Smithey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413277A publication Critical patent/BRPI0413277A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS DE ADSORVATOS DE MEDICAMENTOS AMORFOS E MATERIAIS QUE FORMAM MICROFASES LIPOFìLICAS". Uma composição farmacêutica compreende um adsorvato sólido compreendendo um medicamento adsorvido em um substrato e um material que forma uma microfase lipofílica. O adsorvato sólido também pode ser co-administrado com um material que forma uma microfase lipofílica a um meio de utilização in vivo. As composições da presente invenção aumentam a concentração de medicamento no meio de utilização.
BRPI0413277-7A 2003-08-04 2004-07-23 composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas BRPI0413277A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49241003P 2003-08-04 2003-08-04
PCT/IB2004/002498 WO2005011635A2 (en) 2003-08-04 2004-07-23 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

Publications (1)

Publication Number Publication Date
BRPI0413277A true BRPI0413277A (pt) 2006-10-10

Family

ID=34115618

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413277-7A BRPI0413277A (pt) 2003-08-04 2004-07-23 composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas

Country Status (8)

Country Link
US (2) US9023393B2 (pt)
EP (1) EP1653927B1 (pt)
JP (1) JP2007501218A (pt)
AT (1) ATE540671T1 (pt)
BR (1) BRPI0413277A (pt)
CA (1) CA2532931A1 (pt)
MX (1) MXPA06001417A (pt)
WO (1) WO2005011635A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
EP2548894A1 (en) * 2005-02-03 2013-01-23 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
ATE457721T1 (de) * 2005-05-26 2010-03-15 Flamma Spa An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2072042A1 (en) * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Active pharmaceutical ingredient on solid support, amorphous and with improved solubility
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
WO2010022385A2 (en) * 2008-08-22 2010-02-25 United States Pharmaceutical Distributors, Inc. Container for use in pneumatic transport system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
EP3773509B1 (en) 2018-04-06 2023-11-01 Capsugel Belgium NV Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
CN109901213B (zh) * 2019-03-05 2022-06-07 中国辐射防护研究院 一种基于Reuter网格的γ扫描方案生成方法及系统
WO2022068876A1 (en) 2020-09-29 2022-04-07 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
TW202345842A (zh) 2022-03-25 2023-12-01 大陸商深圳市藥欣生物科技有限公司 Ｐｒｏｔａｃ化合物之醫藥組合物及其用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS57142911A (en) * 1981-02-28 1982-09-03 Furointo Sangyo Kk Absorption-improving agent
EP0129893B1 (en) * 1983-06-28 1991-09-04 Takeda Chemical Industries, Ltd. Ground mixture
US4581232A (en) * 1983-07-20 1986-04-08 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates
GB8413191D0 (en) * 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4711774A (en) * 1986-03-27 1987-12-08 Warner-Lambert Company Medicament adsorbates with complex magnesium aluminum silicate and their preparation
US4716033A (en) * 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
US4717565A (en) * 1986-03-27 1988-01-05 Warner-Lambert Company Process for the preparation of medicament adsorbates
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4835186A (en) * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
JP2792862B2 (ja) 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
SE8803935L (sv) 1988-10-31 1990-05-01 Kabivitrum Ab Laekemedelskomposition
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IE60458B1 (en) 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
FR2679467B1 (fr) * 1991-07-26 1993-10-15 Oreal Dispersion solide d'au moins un alcool polyhydrique dans un milieu anhydre et procede de preparation.
ES2109377T3 (es) * 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
CZ291495B6 (cs) * 1992-09-18 2003-03-12 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
JPH07291854A (ja) 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
AU4314196A (en) 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
US5626878A (en) * 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
SI9500059A (sl) 1995-02-23 1996-08-31 Lek Tovarna Farmacevtskih Postopek za pripravo trdnih površinskih disperzij amorfnih, v vodnih medijih slabo topnih učinkovin in njihova uporaba
JPH08291854A (ja) 1995-04-20 1996-11-05 Zexel Corp 車両用差動装置
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
PT784974E (pt) * 1995-07-26 2003-09-30 Kyowa Hakko Kogyo Kk Preparacao de derivados de xantina numa dispersao solida
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
EP0954570A1 (en) 1996-06-28 1999-11-10 Novo Nordisk A/S A recombinant enzyme with mutanase activity
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
ZA9710927B (en) 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
DE19704243A1 (de) 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
DE19704244A1 (de) * 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US6403587B1 (en) 1997-02-26 2002-06-11 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
EP0989851B1 (en) 1997-07-29 2002-10-02 PHARMACIA & UPJOHN COMPANY Self-emulsifying formulation for acidic lipophilic compounds
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
HN1998000115A (es) 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
AU9297798A (en) 1997-09-16 1999-04-05 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19741400A1 (de) 1997-09-19 1999-03-25 Bayer Ag Benzyl-biphenyle
FR2772271B1 (fr) * 1997-12-11 2000-09-01 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
IL137330A0 (en) 1998-02-05 2001-07-24 Pfizer Prod Inc Novel dihydroxyhexanoic acid derivatives
AU3285499A (en) 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
US20010025046A1 (en) 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
JP2000016934A (ja) * 1998-06-30 2000-01-18 Eisai Co Ltd テプレノンを含有した錠剤
ES2341510T3 (es) * 1998-08-13 2010-06-21 Cima Labs Inc. Microemulsiones como formas farmaceuticas solidas para la administracion oral.
US6376481B2 (en) * 1998-09-02 2002-04-23 Mcneil-Ppc, Inc. Sterol esters in tableted solid dosage forms
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
WO2000018723A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
DK1115693T3 (da) 1998-09-25 2007-07-23 Monsanto Co Substituerede polycykliske aryl- og heteroaryl-Si(tertiære)-heteroalkylaminer der er egnede til inhibering af cholesteryl-esther-transferproteinaktivitet
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
DE60039802D1 (de) 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
JP2000236076A (ja) * 1999-02-15 2000-08-29 Nec Corp 半導体装置及びその製造方法
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
IL144761A0 (en) 1999-12-08 2002-08-14 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
KR100694667B1 (ko) 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
AP2002002553A0 (en) 1999-12-23 2002-06-30 Pfizer Prod Inc Hydrogel-driven Drug Dosoge Form.
AU784340B2 (en) * 1999-12-23 2006-03-16 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
HUP0301130A3 (en) 2000-01-28 2006-07-28 Smithkline Beecham Corp Electrospun pharmaceutical compositions
JP2001316248A (ja) * 2000-02-28 2001-11-13 Eisai Co Ltd 油状薬物含有組成物の製造方法
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US20010053778A1 (en) * 2000-03-16 2001-12-20 Hoover Dennis J. Pharmaceutical compositions of glycogen phosphorylase inhibitors
WO2001095939A1 (en) 2000-06-12 2001-12-20 Smithkline Beecham Corporation Novel solid dispersion compositions
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6602523B1 (en) * 2000-08-17 2003-08-05 Technology Holding, Llc. Composite material and process for increasing bioavailability and activity of a beneficial agent
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
TNSN03138A1 (en) * 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AN AMORPHOUS MEDICINAL PRODUCT
KR100425226B1 (ko) 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
US6796586B2 (en) 2001-07-09 2004-09-28 Twin Bay Medical, Inc. Barb clamp
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
EP1439824A2 (en) * 2001-10-29 2004-07-28 Therics, Inc. Three-dimensional suspension printing of dosage forms
CA2474838C (en) * 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials

Also Published As

Publication number Publication date
EP1653927A2 (en) 2006-05-10
JP2007501218A (ja) 2007-01-25
EP1653927B1 (en) 2012-01-11
MXPA06001417A (es) 2006-05-15
USRE47033E1 (en) 2018-09-11
CA2532931A1 (en) 2005-02-10
US20050031693A1 (en) 2005-02-10
WO2005011635A3 (en) 2005-03-17
ATE540671T1 (de) 2012-01-15
US9023393B2 (en) 2015-05-05
WO2005011635A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
BRPI0413277A (pt) composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
DE60320940D1 (de) Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
EA200301279A1 (ru) Фармацевтические композиции адсорбатов аморфного лекарственного средства
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
ATE381947T1 (de) Zusammensetzungen enthaltend piperacillin und tazobactam zur injektion
IL198870A0 (en) ANTIBODIES THAT BIND TO HUMAN PDGFRa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
IL179250A0 (en) Stable crystal of 4-oxoquinoline compound and pharmaceutical compositions containing the same
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
IL183102A0 (en) Betulin derivatives and pharmaceutical compositions containing the same
IL188732A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
GT200600307A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
BRPI0418378A (pt) combinações de substáncias ativas com propriedades inseticidas
EE05082B1 (et) Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
EP1781277A4 (en) COMBINED COMPOSITION
EP1722821A4 (en) COMPOSITION FOR THE ORAL ADMINISTRATION OF TAMSULOSIN HYDROCHLORIDE AND CONTROLLED RELEASE PELLETING FORMULATION COMPRISING THE SAME
ATE348619T1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
EE200300398A (et) Isoksasoliini derivaat, selle saamine ja kasutamine depresioonivastase ravimi valmistamiseks ning seda sisaldav ravimkompositsioon
ATE413171T1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.